A
Alessandra Tosolini
Researcher at Celgene
Publications - 17
Citations - 1828
Alessandra Tosolini is an academic researcher from Celgene. The author has contributed to research in topics: Enasidenib & Myeloid leukemia. The author has an hindex of 8, co-authored 15 publications receiving 1315 citations.
Papers
More filters
Journal ArticleDOI
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein,Eytan M. Stein,Courtney D. DiNardo,Daniel A. Pollyea,Amir T. Fathi,Gail J. Roboz,Gail J. Roboz,Jessica K. Altman,Richard Stone,Daniel J. DeAngelo,Ross L. Levine,Ian W. Flinn,Hagop M. Kantarjian,Robert H. Collins,Manish R. Patel,Arthur E. Frankel,Anthony S. Stein,Mikkael A. Sekeres,Ronan T. Swords,Bruno C. Medeiros,Christophe Willekens,Christophe Willekens,Paresh Vyas,Alessandra Tosolini,Qiang Xu,Robert Knight,Katharine E. Yen,Sam Agresta,Stéphane de Botton,Stéphane de Botton,Martin S. Tallman,Martin S. Tallman +31 more
TL;DR: Inducing differentiation of myeloblasts, not cytotoxicity, seems to drive the clinical efficacy of enasidenib, a first-in-class, oral, selective inhibitor of mutant-IDH2 enzymes.
Journal ArticleDOI
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Eytan M. Stein,Eytan M. Stein,Courtney D. DiNardo,Amir T. Fathi,Daniel A. Pollyea,Richard Stone,Jessica K. Altman,Gail J. Roboz,Gail J. Roboz,Manish R. Patel,Robert H. Collins,Ian W. Flinn,Mikkael A. Sekeres,Anthony S. Stein,Hagop M. Kantarjian,Ross L. Levine,Paresh Vyas,Kyle J. MacBeth,Alessandra Tosolini,Jason VanOostendorp,Qiang Xu,Ira Gupta,Thomas Lila,Alberto Risueño,Katharine E. Yen,Bin Wu,Eyal C. Attar,Martin S. Tallman,Martin S. Tallman,Stéphane de Botton,Stéphane de Botton +30 more
TL;DR: Enasidenib was well tolerated and induced molecular remissions and hematologic responses in patients with AML for whom prior treatments had failed and clearance of mutant-IDH2 clones was also associated with achievement of CR.
Journal ArticleDOI
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
Daniel A. Pollyea,Martin S. Tallman,Stéphane de Botton,Stéphane de Botton,Hagop M. Kantarjian,Robert H. Collins,Anthony S. Stein,Mark G. Frattini,Qiang Xu,Alessandra Tosolini,Wendy L. See,Kyle J. MacBeth,Samuel V. Agresta,Eyal C. Attar,Courtney D. DiNardo,Eytan M. Stein,Eytan M. Stein +16 more
TL;DR: Oral, outpatient targeted treatment with enasidenib may benefit older adults with newly diagnosed mutant-IDH2 AML who are not candidates for cytotoxic regimens.
Journal ArticleDOI
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.
James J. Harding,Maeve A. Lowery,Alan H. Shih,Juan M. Schvartzman,Shengqi Hou,Christopher Famulare,Minal Patel,Mikhail Roshal,Richard K. G. Do,Ahmet Zehir,Daoqi You,S. Duygu Selcuklu,Agnes Viale,Martin S. Tallman,David M. Hyman,Ed Reznik,Lydia W.S. Finley,Elli Papaemmanuil,Alessandra Tosolini,Mark G. Frattini,Kyle J. MacBeth,Guowen Liu,Bin Fan,Sung Choe,Bin Wu,Yelena Y. Janjigian,Ingo K. Mellinghoff,Luis A. Diaz,Ross L. Levine,Ghassan K. Abou-Alfa,Eytan M. Stein,Andrew M. Intlekofer +31 more
TL;DR: Four clinical cases are described that identify mutant IDH isoform switching, either from Mutant IDH1 to mutant IDh2 or vice versa, as a mechanism of acquired clinical resistance to IDH inhibition in solid and liquid tumors.
Journal ArticleDOI
Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial
Eytan M. Stein,Courtney D. DiNardo,Jessica K. Altman,Robert H. Collins,Daniel J. DeAngelo,Hagop M. Kantarjian,Mikkael A. Sekeres,Amir T. Fathi,Ian W. Flinn,Arthur E. Frankel,Ross L. Levine,Bruno C. Medeiros,Manish R. Patel,Daniel A. Pollyea,Gail J. Roboz,Richard Stone,Ronan T. Swords,Martin S. Tallman,Katherine Yen,Eyal C. Attar,Qiang Xu,Alessandra Tosolini,Jay M. Mei,Anjan Thakurta,Robert Knight,Stéphane de Botton +25 more
TL;DR: AG-221 safety and efficacy results with a focus on pts with RR-AML, and the first AG-221 data to show changes in absolute neutrophil count (ANC) in early Tx and associated adverse events (AEs), response by m IDH2 type (R140Q or R172K), and mIDH2 variant allele frequency (VAF) on Tx over time are reported.